loading
前日終値:
$38.10
開ける:
$37.95
24時間の取引高:
832.92K
Relative Volume:
0.67
時価総額:
$7.31B
収益:
$29.52M
当期純損益:
$-567.06M
株価収益率:
-10.20
EPS:
-3.66
ネットキャッシュフロー:
$-551.11M
1週間 パフォーマンス:
-1.99%
1か月 パフォーマンス:
-4.43%
6か月 パフォーマンス:
-15.44%
1年 パフォーマンス:
+15.89%
1日の値動き範囲:
Value
$37.03
$38.11
1週間の範囲:
Value
$37.03
$39.59
52週間の値動き範囲:
Value
$29.55
$62.40

Revolution Medicines Inc Stock (RVMD) Company Profile

Name
名前
Revolution Medicines Inc
Name
セクター
Healthcare (1166)
Name
電話
415-766-3638
Name
住所
700 SAGINAW DR, REDWOOD CITY, CA
Name
職員
0
Name
Twitter
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
RVMD's Discussions on Twitter

RVMD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RVMD
Revolution Medicines Inc
37.35 7.31B 29.52M -567.06M -551.11M -3.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-07-16 繰り返されました Needham Buy
2024-07-12 開始されました Barclays Overweight
2024-07-08 開始されました Jefferies Buy
2024-04-12 繰り返されました Needham Buy
2024-04-10 アップグレード Raymond James Outperform → Strong Buy
2024-03-11 開始されました Piper Sandler Overweight
2024-01-05 アップグレード BofA Securities Neutral → Buy
2024-01-04 開始されました Wedbush Outperform
2023-11-16 開始されました Raymond James Outperform
2023-02-28 アップグレード JP Morgan Neutral → Overweight
2022-12-14 開始されました Needham Buy
2022-10-21 開始されました Oppenheimer Outperform
2022-05-20 開始されました BofA Securities Neutral
2022-03-01 アップグレード Stifel Hold → Buy
2021-09-23 開始されました Stifel Hold
2021-08-12 ダウングレード Goldman Buy → Neutral
2021-05-18 開始されました Goldman Buy
2020-05-21 開始されました H.C. Wainwright Buy
2020-03-09 開始されました Cowen Outperform
2020-03-09 開始されました Guggenheim Buy
2020-03-09 開始されました JP Morgan Neutral
すべてを表示

Revolution Medicines Inc (RVMD) 最新ニュース

pulisher
Mar 24, 2025

Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock - Investing.com

Mar 24, 2025
pulisher
Mar 20, 2025

Revolution Medicines executive sells shares worth $128,598 By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Revolution Medicines’ general counsel sells $56,920 in stock By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 19, 2025

Revolution Medicines CEO Mark Goldsmith sells $458,255 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

Revolution Medicines CFO Jack Anders sells $72,771 in stock By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 19, 2025

Revolution Medicines’ general counsel sells $56,920 in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Revolution Medicines CFO Jack Anders sells $72,771 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Revolution Medicines Executives Sell Shares - TradingView

Mar 19, 2025
pulisher
Mar 15, 2025

Revolution Medicines Inc (RVMD) Should Be Considered For The Next Few Weeks - Stocks Register

Mar 15, 2025
pulisher
Mar 13, 2025

Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 20 - GuruFocus.com

Mar 13, 2025
pulisher
Mar 13, 2025

Revolution Medicines at Leerink Conference: Expanding RAS Inhibitor Reach By Investing.com - Investing.com Canada

Mar 13, 2025
pulisher
Mar 12, 2025

Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials - Investing.com Canada

Mar 12, 2025
pulisher
Mar 12, 2025

Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 11, 2025

Revolution Medicines at Barclays Conference: Focus on Pancreatic Cancer Trials - Investing.com UK

Mar 11, 2025
pulisher
Mar 06, 2025

Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey

Mar 06, 2025
pulisher
Mar 04, 2025

10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey

Mar 04, 2025
pulisher
Mar 04, 2025

Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

HC Wainwright Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now - Yahoo Finance

Mar 03, 2025
pulisher
Mar 03, 2025

10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey

Mar 03, 2025
pulisher
Mar 02, 2025

Revolution Medicines’ (RVMD) “Outperform” Rating Reiterated at Wedbush - Armenian Reporter

Mar 02, 2025
pulisher
Mar 01, 2025

Long Term Trading Analysis for (RVMD) - Stock Traders Daily

Mar 01, 2025
pulisher
Mar 01, 2025

Wedbush Reaffirms Outperform Rating for Revolution Medicines (NASDAQ:RVMD) - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus.com

Feb 28, 2025
pulisher
Feb 27, 2025

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com

Feb 27, 2025
pulisher
Feb 27, 2025

Revolution stock price target cut to $59 at Needham - Investing.com

Feb 27, 2025
pulisher
Feb 27, 2025

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Feb 27, 2025
pulisher
Feb 27, 2025

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Feb 27, 2025
pulisher
Feb 26, 2025

Revolution Medicines Reports 2024 Financial Results and Progress - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Earnings call transcript: Revolution Medicines Q4 2024 reflects strategic advancements - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Revolution Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 26, 2025
pulisher
Feb 26, 2025

Revolution Medicines Q4 Net Loss Narrows -February 26, 2025 at 05:13 pm EST - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Earnings Flash (RVMD) Revolution Medicines Q4 Loss of $1.12 per Share vs. FactSet Est Loss of $0.99 - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Revolution Medicines, Inc. SEC 10-K Report - TradingView

Feb 26, 2025
pulisher
Feb 26, 2025

Can Revolution Medicines' $2.3B War Chest Overcome Mounting Losses in Cancer Drug Race? - StockTitan

Feb 26, 2025
pulisher
Feb 25, 2025

Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 2024 Result - Yahoo Finance

Feb 25, 2025
pulisher
Feb 24, 2025

Revolution Medicines to Participate in March 2025 Investor Conferences - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Can Revolution Medicines' Triple Conference Appearance Signal Major Clinical Updates? - StockTitan

Feb 24, 2025
pulisher
Feb 24, 2025

Rhumbline Advisers Acquires 24,473 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - Defense World

Feb 24, 2025
pulisher
Feb 24, 2025

Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers | Journal of Medicinal Chemistry - ACS Publications

Feb 24, 2025
pulisher
Feb 24, 2025

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $66.25 Consensus Target Price from Brokerages - Defense World

Feb 24, 2025
pulisher
Feb 24, 2025

Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday - Defense World

Feb 24, 2025
pulisher
Feb 19, 2025

Revolution Medicines to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Nasdaq

Feb 19, 2025
pulisher
Feb 19, 2025

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - The Manila Times

Feb 19, 2025
pulisher
Feb 19, 2025

Revolution Medicines to Report Financial Results for Fourth - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Revolution Medicines Q4 Earnings Coming: Will Their Cancer Drug Pipeline Show Progress? - StockTitan

Feb 19, 2025

Revolution Medicines Inc (RVMD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):